Patents Examined by Jared D Barsky
  • Modulators of HSP70/DnaK function and methods of use thereof
    Patent number: 9296687
    Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 29, 2016
    Assignees: Fox Chase Cancer Center, The Trustees of the University of Pennsylvania
    Inventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy
  • N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators
    Patent number: 9284312
    Abstract: The present invention is directed to N-methyl tetrahydroquinoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: March 15, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Christina Ng DiMarco, Thomas J. Greshock
  • Tetracycline compositions
    Patent number: 9278105
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: March 8, 2016
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: David C. Griffith, Serge Boyer, Michael N. Dudley, Scott Hecker
  • Treatment of type 1 diabetes
    Patent number: 9271984
    Abstract: The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: March 1, 2016
    Assignee: POXEL
    Inventors: Pascale Fouqueray, Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze
  • Methods for microbial biofilm destruction
    Patent number: 9271493
    Abstract: Compositions and methods for the dissolution of a microbial biofilm are provided, where the method comprises contacting a microbiofilm with an effective dose of a curcumin derivative as a biofilm inhibitor. In some embodiments the curcumin derivative is dimethoxycurcumin. In some embodiments the biofilm comprises E. coli, e.g. including uropathogenic E. coli. The biofilm can be present in vitro or in vivo. The biofilm inhibitor may be administered alone, or in combination with bacteriocidal agents.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: March 1, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lynette Cegelski, Ji Youn Lim
  • Methods for treatment of bacterial infections
    Patent number: 9273341
    Abstract: The peptidoglycan layer is a vital component of the bacterial cell wall, which comprises 4?3 and 3?3 transpeptide cross-linkages, the formation of which are catalyzed by D,D- and L,D-transpeptidases, respectively. Methods for the treatment of bacterial infections with agents that inhibit L,D-transpeptidases, either alone or in combination with D,D-transpeptidase inhibitors, are provided herein. Also provided are methods for the treatment of chronic stage tuberculosis with agents that inhibit enzyme with L,D-transpeptidase activity.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: March 1, 2016
    Assignees: The Johns Hopkins University, Institut National de la Sante et de la Recherche Medicale
    Inventors: Gyanu Lamichhane, William R. Bishai, Radhika Gupta, Marie Lavollay, Jean-Luc Mainardi, Michel Arthur
  • 5?-androstane-3?,5,6?-triol injection and preparation method therefor
    Patent number: 9265837
    Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: February 23, 2016
    Assignee: Guangzhou Cellprotek Pharmaceuticals Ltd.
    Inventors: Guangmei Yan, Haiyan Hu, Jingxia Zhang, Pengxin Qiu, Ling Li, Ning Tian
  • Anti-aging composition containing phloretin
    Patent number: 9248082
    Abstract: An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the composition contains ascorbic acid, water is present as a co-solvent.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: February 2, 2016
    Assignee: L'OREAL
    Inventors: Sheldon R. Pinnell, Jan Zielinski, Isabelle Hansenne
  • Preparation and uses of obeticholic acid
    Patent number: 9238673
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 19, 2016
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Therapeutic agent for lower urinary tract disease
    Patent number: 9226926
    Abstract: A method of treating a condition chosen from the group consisting of interstitial cystitis, cystitis, chronic nonbacterial prostatitis, chronic cystitis, prostatic hyperplasia, prostatitis, prostatism, bladder neck contracture, bladder inflammation, and overactive bladder by administering an amount of rebamipide or a pharmaceutically acceptable salt thereof to a human.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: January 5, 2016
    Assignee: N.M.A. CO., LTD.
    Inventors: Tomohiro Ueda, Yasuhito Funahashi
  • Shapeable bone graft substitute and instruments for delivery thereof
    Patent number: 9220595
    Abstract: Injectable bone graft material having a biocompatible, resorbable polymer and a biocompatible, resorbable inorganic material exhibiting macro, meso, and microporosities.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: December 29, 2015
    Assignee: Orthovita, Inc.
    Inventors: Charanpreet S. Bagga, Theodore D. Clineff, Erik M. Erbe, Michael W. Paris, Gina M. Nagvajara, Antony Koblish
  • Compounds for the treatment of pathologies associated with aging and degenerative disorders
    Patent number: 9220711
    Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: December 29, 2015
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
  • Composition containing arylnaphthalene lignan derivative for preventing and/or treating dementia
    Patent number: 9211278
    Abstract: Composition and method for preventing and/or treating dementia and ameliorating memory impairment and/or improving memory, comprising one or more arylnaphthalene lignan derivatives, namely Justicidin A, 5-methoxyjusticidin A, Chinensinaphthol, and a pharmaceutically-acceptable salt thereof, as active ingredient.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: December 15, 2015
    Assignees: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, CSIR
    Inventors: Hyun Ok Yang, Sung-Kwon Chung, Hak Cheol Kwon, Jin Wook Cha, Young-Joo Kim, Gerda Fouche, Rudzani Nthambeleni, Dashnie Naidoo, Jeremiah Senabe, Vinesh Jaichand Maharaj, Eric Khorombi, Jungyeob Ham, Joon Ki Kim
  • Pharmaceutical topical composition of mupirocin
    Patent number: 9205149
    Abstract: Anhydrous topical gel composition of mupirocin or its salts comprising: a) a lipophilic base selected from the group consisting of petrolatum, medium-chain triglycerides, isopropyl myristate and mixtures thereof; b) a bioadhesive selected from the group comprising polyvinylpyrrolidone and polymethacrylates; and c) a solvent selected from the group comprising ethanol, propanol, and isopropanol; which is stable and shows an increased residence time of the active ingredient in the skin, resulting in an improved clinical effect in the treatment of bacterial skin infections while maintaining the safety profile of the commercial pharmaceutical product.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: December 8, 2015
    Assignee: LABORATORIOS OJER PHARMA, S.L.
    Inventors: Carlos González Ojer, Beatriz Goñi Allo, Fiona Pastor Fernández, Cayetana Yárnoz De Miguel
  • Onapristone polymorphic forms and methods of use
    Patent number: 9193757
    Abstract: Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 24, 2015
    Assignee: ARNO THERAPEUTICS, INC.
    Inventor: Stefan Proniuk
  • Glycerin polysilicones
    Patent number: 9186311
    Abstract: The present invention is directed to a series of glycerin polysilicones. By glycerin polysilicones in meant polymers that have silicone portions that are functionalized with glycerin groups. The polymers of the present invention can range from relatively low molecular weight (around 600 daltons) to higher molecular weight (of about 2,500 daltons). The presence of the glyceryl groups together with the silicone groups allows for the preparation of molecules uniquely suited to personal care applications, more specifically, skin care products.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: November 17, 2015
    Assignee: Surfa Tech Corporation
    Inventor: Thomas George O'Lenick
  • Medicament for liver regeneration and for treatment of liver failure
    Patent number: 9186381
    Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: November 17, 2015
    Assignees: Helmholtz Zentrum Fuer Infektionsforschung GmbH, Medizinische Hochschule Hannover
    Inventors: Lars Zender, Torsten Wuestefeld
  • Aspirin derivatives and uses thereof
    Patent number: 9187402
    Abstract: The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: November 17, 2015
    Assignee: North Carolina Agricultural and Technical State University
    Inventor: Shengmin Sang
  • Treatment and inhibition of protozoal diseases with nandrolone and its derivatives
    Patent number: 9173888
    Abstract: This invention provides new therapeutic potential of nandrolone or a derivative thereof, against protozoal diseases. More specifically, nandrolone or a derivative thereof exhibits anti-protozoal activity against Leishmania major. Anti-protozoal potential of nandrolone derivatives, such as compounds 1-8, can contribute in the development of effective therapies against protozoal diseases, such as leishmaniasis, trypanosomiasis, malaria, toxoplasmosis, babeosis, amoebic dysentery and lambliasis. Another aspect of the invention is a method of testing derivatives of nandrolone for anti-protozoal activity comprising growing Leishmania in the presence of the test derivative and determining the IC50 value.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: November 3, 2015
    Inventors: Elias Baydoun, Muhammad Iqbal Choudhary, Atia-tul- Wahab, Colin Smith, Martin Karam, Dina Farran, Mahwish Shafi Ahmed Khan, Malik Shoaib Ahmad
  • Adamantyl derivatives as therapeutic agents
    Patent number: 9168237
    Abstract: The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: October 27, 2015
    Assignee: Women & Infants' Hospital of Rhode Island
    Inventors: Richard G. Moore, Rakesh K. Singh